News

As per the terms of the agreement, Cambrex has sold the development and commercialization rights for the drug products to Tillotts which are based on 5-ASA-based technology. In

Further, Karl-Hermann Schlingensiepen, the current CEO of the company, has changed from the operative management of Antisense Pharma to a strategic consulting function. He will concentrate on consulting

In addition to that the company expects to begin a Phase 2 trial to evaluate combination of TMC435 and Pharmasset’s PSI-7977 for CHC treatment. The primary endpoint of

The antimicrobial solution found in the Ophthalmic Wash and Otic Rinse inhibits antibiotic-resistant strains of bacteria (including staph and MRSA) as well as fungi, viruses and spores. Innovacyn

NOA also includes other formulations of cystamine and cysteamine. The patent application 11/990,869 covers the use of any composition of cysteamine or cystamine that provides increased delivery to

PSI-7977 is Pharmasset’s experimental nucleotide polymerase inhibitor and TMC435 is an experimental protease inhibitor of Tibotec. In the trial, the companies expect to investigate the pharmacokinetics, safety and

With this approval, the company has received approval for its complete product line of amlodipine / benazepril. The US subsidiary of Lupin Limited, LPI’s amlodipine / benazepril capsules

The funding will be used to further develop Ark’s lentiviral vector production technology using baculoviruses (Baculo-lentiviral) to achieve required scale and GMP quality for clinical use. Additionally, Ark

Additionally, Almirall has also received German approval for Actikerall as a treatment hyperkeratotic actinic keratosis (grade I/II) in adult patients. Almirall is set to launch Actikerall in German